GRI Bio GRI 深滬

已收盤 08-01 16:00:00 美东时间

1.32

+0.040

+3.13%

華盛通

立即下載

最高1.37
今開1.30
成交量 28.02万股
最低 1.21
昨收 1.28
總市值 386.46万
52周最高 30.43
市盈率 ^靜 --
換手率 9.57%
52周最低 1.10
委比 -16.93%
總股本 292.77万
歷史最高 2314002.60
量比 0.51
振幅 12.50%
歷史最低 1.21
每手 1
風險率 4.83%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

ESG观察｜从“火车上的童年”到校园补贴：上市公司“二代”福利政策引发三个问号

每经记者｜黄宗彦每经编辑｜陈俊杰 7月31日，“京东黑板报”宣...

08-01 19:35
12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Soligenix (NASDAQ:SNGX) shares rose 192.0% to $3.65 during Thursday's ...

08-01 01:08
GRI Bio Announces Positive Interim Data for GRI-0621

GRI Bio ( ($GRI) ) has provided an update. On July 31, 2025, GRI Bio announced ...

07-31 21:27
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

GRI Bio, Inc. participated in a virtual investor segment to discuss interim biomarker data from its Phase 2a study on idiopathic pulmonary fibrosis (IPF). The company, focused on NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, highlighted its lead program GRI-0621, an iNKT cell inhibitor, and its pipeline of dNKT agonists for conditions like systemic lupus erythematosus. GRI Bio's extensive compound library suppo...

07-31 17:50
董秘说|通裕重工董秘王子：ESG不再是“选择题” 而是企业生存与成长的“必答题”

登录新浪财经APP 搜索【信披】查看更多考评等级专题：金麒麟|2025金牌董秘评选　　炒股就看金麒麟分析师研报，权威，专业，及时，全面...

07-31 17:45
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio reports interim 6-week data from its Phase 2a study of GRI-0621 for IPF, showing positive impacts on fibrogenesis, fibrolysis, and potential repair mechanisms. The Independent Data Monitoring Committee (IDMC) recommended continuing the study as planned, citing no safety concerns. The Phase 2a trial, fully enrolled, is on track to deliver topline data in Q3 2025. Currently, IPF treatments are limited to two approved drugs with significant ...

07-31 13:00
波司登发布ESG报告：引领可持续时尚创新赋能产品迭代升级

联合国全球契约组织提出ESG（环境、社会和治理）概念刚刚超过20个年头，可持续发展日渐成为全球共识与目标，也成为企业发展的新趋势、新要求。被称作上市公司“第二财...

07-30 17:24
Grainger CEO Increases Stake Through Dividend Reinvestment

The latest update is out from Grainger ( ($GB:GRI) ). Grainger PLC, a company i...

07-30 17:13
港E声|一文看懂港交所ESG监管进阶：从“管披露”到“管能力”螺旋升级

本文来源：时代商业研究院作者：祝箐来源丨时代商业研究院作者丨特约研究员祝箐近日，港交所宣布，所有主板及GEM上市公司（即香港所有公众公司）的董...

07-29 21:19
Republic Services Marks Emissions Reduction Milestone in Latest Sustainability Report

20% reduction in greenhouse gas (GHG) emissions outpaces interim 2025 target; Safety and Talent results exceed industry benchmarks PHOENIX, July 28, 2025 /PRNewswire/ -- Republic Services, I...

07-28 21:04

派息除權日	每股總股息	派息日期
2023-03-23	0.63	2023-03-28
2022-12-22	0.53	2022-12-29
2022-09-22	0.45	2022-09-29
2022-06-23	0.48	2022-06-30
2022-03-24	0.52	2022-03-31
2021-12-22	0.56	2021-12-29
2021-09-23	0.44	2021-09-30
2021-06-17	0.47	2021-06-24
2021-03-18	0.51	2021-03-25
2020-12-22	0.64	2020-12-30
2020-09-17	0.35	2020-09-24
2020-06-18	0.42	2020-06-25
2020-03-19	0.68	2020-03-26
2019-12-19	0.51	2019-12-27
2019-09-19	0.27	2019-09-26
2019-06-20	0.37	2019-06-27
2019-03-21	0.35	2019-03-28
2018-12-20	0.41	2018-12-27
2018-09-20	0.22	2018-09-27
2018-06-21	0.44	2018-06-28
2018-03-22	0.22	2018-03-29
2017-12-21	0.95	2017-12-28
2017-09-21	0.33	2017-09-27
2017-06-21	0.35	2017-06-28
2016-12-21	0.46	2016-12-29
2016-09-21	0.38	2016-09-28
2016-06-22	0.31	2016-06-29
2016-03-23	0.37	2016-03-31
2015-12-23	0.21	2015-12-31
2015-09-23	0.13	2015-09-30
2015-06-24	0.68	2015-07-01
2015-03-25	0.44	2015-04-01
2014-12-24	0.41	2015-01-02
2014-09-24	0.24	2014-10-01
2014-06-25	0.39	2014-07-02
2014-03-26	0.22	2014-04-02
2013-12-26	0.17	2014-01-03
2013-09-25	0.23	2013-10-02
2012-12-26	2.23	2013-01-03
2012-09-26	0.23	2012-10-03
2012-06-20	0.26	2012-06-27
2012-03-21	0.15	2012-03-28
2011-12-21	0.18	2011-12-28
2011-09-21	0.20	2011-09-28
2011-06-22	0.28	2011-06-29
2011-03-23	0.61	2011-03-30
2010-12-21	1.12	2010-12-29
2010-09-22	0.18	2010-09-29
2010-06-23	0.21	2010-06-30
2010-03-24	0.43	2010-03-31
2009-12-29	1.03	2010-01-06
2009-09-29	0.08	2009-10-06
2009-06-29	0.57	2009-07-07
2008-12-29	0.49	2009-01-05

公司名稱	GRI Bio
行業分類	--
業務描述	GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

GRI Bio GRI 深 滬

1.32

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

GRI Bio GRI 深滬